Ipsen’s Iqirvo receives FDA approval to treat adults with primary biliary cholangitis

12 Jun 2024
·
Deals
pmlive.com
Clinical ResultDrug ApprovalPhase 3
Ipsen’s Iqirvo receives FDA approval to treat adults with primary biliary cholangitis
Preview
Source: PMLiVE
Ipsen’s Iqirvo (elafibranor) has been granted accelerated approval from the US Food and Drug Administration (FDA) to treat adult patients with primary biliary cholangitis (PBC).
The oral, once-daily peroxisome proliferator-activated receptor agonist has been approved in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as a monotherapy in patients unable to tolerate UDCA.
Affecting approximately 100,000 people in the US, PBC is a rare, autoimmune, cholestatic liver disease that occurs when a buildup of bile and toxins, along with chronic inflammation, causes irreversible scarring of the liver and destruction of the bile ducts.
If left untreated, the lifelong condition can progress, leading to liver failure and potentially the need for a liver transplant.
The FDA’s decision was based on results from the phase 3 ELATIVE trial, published in the New England Journal of Medicine, which demonstrated that 13 times more patients achieved the composite primary endpoint of biochemical response when treated with Iqirvo plus UDCA compared to placebo plus UDCA.
Secondary endpoints demonstrated normalisation in alkaline phosphatase (ALP), a biochemical marker used as a surrogate endpoint in PBC trials, levels in 15% of Iqirvo-treated patients versus 0% for placebo plus UDCA.
Marked as “the first new medicine for PBC in nearly a decade”, Christelle Huguet, executive vice president, head of research and development, Ipsen, added: “Iqirvo demonstrated statistically significant improvements in biochemical response compared to UDCA alone [and] is therefore a much-needed treatment option.”
Dr Kris Kowdley, director, Liver Institute Northwest, Washington and primary investigator on the study, said: “The approval of Iqirvo will allow healthcare providers in the US to address an unmet need with the potential to significantly reduce ALP levels for our patients with PBC.”
Iqirvo was discovered and developed by Genfit and Ipsen licensed the exclusive worldwide rights (except in China, Hong Kong, Taiwan and Macau) to the drug in 2021.
Applications for Iqirvo have also been submitted to the European Medicines Agency and the Medicines and Healthcare products Regulatory Agency, with final regulatory decisions expected in the second half of 2024.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.